Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Roots Analysis | PRODUCT CODE: 1762526

Cover Image

PUBLISHER: Roots Analysis | PRODUCT CODE: 1762526

Human Microbiome Market Distribution : Industry Trends and Global Forecasts by Type of Product, Type of Molecule, Target Indication, Therapeutic Area, Route of Administration and Key Geographical Regions

PUBLISHED:
PAGES: 552 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4799
PDF (One-Location Site License)
USD 6999
PDF (Department License)
USD 10599
PDF (Enterprise License)
USD 17999

Add to Cart

Description

Table of Contents

List of Tables

HUMAN MICROBIOME MARKET: OVERVIEW

As per Roots Analysis, the global human microbiome market is estimated to grow from USD 791 million in the current year to USD 6,091 million by 2035, at a CAGR of 20.4% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Product

  • Probiotic Drugs
  • Other Drugs

Type of Molecule

  • Small Molecules
  • Biologics

Target Indication

  • Colorectal Cancer
  • Diabetes Mellitus
  • Inflammatory Bowel Disease
  • Irritable Bowel Syndrome
  • Graft vs. Host Disease
  • Necrotizing Enterocolitis
  • Primary Hyperoxaluria
  • Recurrent CDI

Therapeutic Area

  • Digestive and Gastrointestinal Disorders
  • Infectious Diseases
  • Metabolic Disorders
  • Oncological Disorders
  • Rare Disorders

Route of Administration

  • Oral
  • Rectal

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

HUMAN MICROBIOME MARKET: GROWTH AND TRENDS

The term microorganism were previously associated with harmful disease-causing agents, until the discovery of certain beneficial microbial colonies in the human system. Humans and a variety of microbial species of bacteria, yeast and protozoa, are known to co-exist in mutually beneficial relationships. Moreover, it is estimated that the human gut microbiome consists of about 100 trillion microorganisms. Notably, this figure significantly outnumbers the total number of cells in the human body.

Human Microbiome Market - IMG1

The majority of microorganisms provide significant benefits to humans by conferring traits and capabilities that would otherwise be absent. The healthy variety of bacteria in the gut has significant potential to enhance immunity and offer a wide range of health benefits. This has led to extensive research and development efforts by human microbiome based live biotherapeutics / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic. In addition, owing to the strong association between the human microbiome and health, a myriad of therapeutic interventions based on manipulation of commensal microbes are under development.

HUMAN MICROBIOME MARKET: KEY INSIGHTS

The report delves into the current state of the human microbiome market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Presently, over 70 companies, worldwide, have taken initiatives to develop therapies that can manipulate the human microbiome; the market is characterized by the presence of small companies.
  • The pipeline features 230+ human microbiome therapeutics that are currently being evaluated across different phases of development; the majority of these are designed for oral delivery.
  • Nearly 30% of the pipeline drugs are in clinical phase of development, while more than 150 drugs are in preclinical and discovery stages. Clinical stage drugs are primarily being developed for infectious diseases and digestive disorders, while candidates in preclinical and discovery stages are focused on oncological disorders.
  • Currently, over 40 companies, worldwide, are engaged in providing various diagnostics and screening / profiling test kits for the purpose of disease detection and analysis of human microflora composition and function.
  • More than 75 diagnostics and screening / profiling test are available / under development.

Of these, around 80% of the tests are available in the market, while rest are under development.

  • Over 70 microbiome focused diagnostic and screening / profiling tests are available in the market; such test kits allow testing of different sample types across various therapeutic areas.
Human Microbiome Market - IMG2
  • Presently, FMTs are the only commercially available microbiome product; in fact, more than 400 clinical trials evaluating FMTs, sponsored by non-industry players, have been registered in the past decade.
  • Several well-funded start-ups have entered this domain; our proprietary start-up health indexing analysis confirms the presence of a number of players that offer significant promise in developing microbiome therapeutics.
  • The rising interest is also reflected in the wide array of partnerships being established between various stakeholders in the recent past; research agreements emerged as the most popular type of partnership model.
  • Partnership activity in this domain increased at a CAGR of 26%, since 2017. It is worth highlighting that majority of the deals were R&D agreements, representing over 35% of the total number of partnerships signed in the given time period.
  • Numerous investors, having realized the benefits and future opportunities of microbiome therapeutics in the treatment of various disorders, have invested more than USD 1 billion in start-ups, since 2019.
  • Of the total amount invested, over USD 563 million was raised through venture capital financing, representing over 56% of the overall funding activity in this domain. Further, 36 instances of grants / awards were also reported, wherein players collectively raised more than USD 137 million.
  • More than 25 industry players claim to be engaged in the manufacturing of microbiome-based biologics for various therapeutic purposes; majority of these firms are headquartered in Europe.
  • Driven by ongoing research and advancements, the human microbiome therapeutics and diagnostics market is anticipated to grow at a significant pace in the coming years.
  • Specifically, the human microbiome therapeutics market is anticipated to grow at a CAGR of 20.4%; the opportunity is likely to be well-distributed across different products, therapeutic areas and geographies.
Human Microbiome Market - IMG3
  • In the coming decade, we anticipate the opportunity for microbiome diagnostics market to grow at an annualized rate of ~53% across different supply channels.
  • As late-stage therapeutics will get approved by the FDA in the foreseen future, microbiome therapeutics are anticipated to capture more than 60% share of total microbiome market by 2035.

Example Players in the Human Microbiome Market

  • 4D Pharma
  • Biosotia Microbiomics
  • DNA Genotek
  • Finch Therapeutics
  • GoodGut
  • Infant Bacterial Therapeutics
  • Invivo Healthcare
  • MaaT Pharma
  • OxThera
  • Qu Biologics
  • Rebiotix
  • Seres Therapeutics
  • Servatus
  • Shoreline Biome

HUMAN MICROBIOME MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global human microbiome market, focusing on key market segments, including [A] type of product, [B] type of molecule, [C] target indication, [D] therapeutic area, [E] route of administration and [F] key geographical regions.
  • Microbiome Therapeutics Market Landscape: A comprehensive evaluation of microbiome therapeutics, based on several relevant parameters, such as [A] phase of development of product candidates, [B] type of molecule, [C] type of therapy, [D] target indication(s), [E] therapeutic area(s), [F] route of administration, [G] type of drug formulation, [H] type of microbiome therapy, [I] combination drug, [J] dosing frequency and [K] special drug designations (if any). Additionally, a comprehensive evaluation of the microbiome companies engaged in the development of microbiome therapeutics, based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
  • Microbiome Therapeutics Company and Drug Profiles: In-depth profiles of key players that are currently engaged in the development of microbiome therapeutics, focusing on [A] overview of the company, [B] financial information (if available) [C] microbiome-based drug portfolio, [D] information on clinical trial and [E] recent developments and an informed future outlook. Additionally, in-depth profiles of key players that are currently engaged in more than six therapeutic programs, focusing on [A] overview of the company, [B] financial information (if available), [C] drug portfolio and [D] informed future outlook.
  • Microbiome Diagnostics and Screening / Profiling Tests Market Landscape: A comprehensive evaluation of various types of microbiome diagnostic and screening / profiling tests, based on several relevant parameters, such as [A] stage of development, [B] type of sample analyzed, [C] type of screening technique. [D] target indication(s), [E] key therapeutic area(s) and [F] purpose of diagnosis. Additionally, a comprehensive evaluation of diagnostics and screening / profiling test providers(s), based on several relevant parameters, such as [A] year of establishment, [B] company size and [C] location of headquarters.
  • Microbiome Diagnostics and Screening / Profiling Tests Providers Company Profiles: In-depth profiles of key players that are currently engaged in the development of microbiome diagnostics and screening / profiling tests, focusing on [A] overview of the company, [B] financial information (if available) [C] diagnostic or screening / profiling test portfolio and [D] recent developments and an informed future outlook.
  • Clinical Trial Analysis: An insightful analysis of clinical trials related to fecal transplant, based on several parameters, such as [A] trial status, [B] trial registration year, [C] trial phase, [D] year-wise trend of completed and recruiting trials, [E] study design, [F] number of patients enrolled, [G] age category of the patients enrolled, [H] type of sponsor / collaborator, [I] active industry and non-industry players, and [J] location of the trials. Furthermore, an insightful analysis of various stool banks based on [A] year of establishment and [B] location of headquarters, along with brief profiles of the most prominent stool banks located across the globe.
  • Attractiveness Competitiveness (AC) Matrix: A comprehensive business portfolio analysis based on an attractiveness and competitiveness (AC) framework, featuring the current market attractiveness and competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.
  • Start-Up Health Indexing: An assessment of the start-ups / small-sized players that are engaged in the development of microbiome therapeutics and diagnostics, based on relevant parameters, such as [A] number of microbiome therapeutics under development, [B] diversity of product portfolio, [C] funding amount, [D] partnership activity and [E] disease indication(s) being treated.
  • Key Therapeutic Areas: In-depth analysis of the most commonly targeted therapeutic indications and information on microbiome-based drugs that are being developed against them, based on [A] key epidemiological facts about specific diseases, [B] available methods of diagnosis and [C] currently available treatment options and their side effects.
  • Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the human microbiome market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of product, [D] target indication, [E] therapeutic area, [F] type of company, [G] type of partner, [H] most active players and [I] geographical distribution of the partnership activity.
  • Funding and Investments: An in-depth analysis of the fundings raised by human microbiome companies, based on relevant parameters, such as [A] year of investment, [B] amount invested, [C] type of funding, [D] type of company, [E] purpose of funding, [F] type of product, [G] target indication, [H] therapeutic area, [I] geographical analysis, [J] most active players and [K] most active investors.
  • Case Study: A detailed discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with information of contract manufacturers, focusing on [A] year of establishment, [B] location of headquarters, [C] company size, [D] scale of operation, [E] type of product manufactured and [F] type of formulation. Additionally, a detailed discussion on the key considerations that are required for selecting a CMO / CRO partner.
  • Big Data and Microbiome Therapeutics: A comprehensive assessment of the emerging role of big data, representing efforts made to develop and implement various algorithms / tools to analyze data generated from microbiome research. Further, a detailed google trends analysis demonstrating a rising interest in stakeholders to use big data tools for supporting microbiome research over the past decade.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older
Show more
Product Code: RA100346

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
    • 1.2.1. Research Assumptions
    • 1.2.2. Project Methodology
    • 1.2.3. Forecast Methodology
    • 1.2.4. Robust Quality Control
    • 1.2.5. Key Considerations
      • 1.2.5.1. Demographics
      • 1.2.5.2. Economic Factors
      • 1.2.5.3. Government Regulations
      • 1.2.5.4. Supply Chain
      • 1.2.5.5. COVID Impact / Related Factors
      • 1.2.5.6. Market Access
      • 1.2.5.7. Healthcare Policies
      • 1.2.5.8. Industry Consolidation
  • 1.3 Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Concept of Microbiota and Microbiome
    • 3.2.1. Discovery of the Human Microbiome
    • 3.2.2. Functions of the Human Microbiome
  • 3.3. Overview of Gut Flora
    • 3.3.1. Role of Gut Flora in Human Health
    • 3.3.2. Factors Affecting Gut Flora
      • 3.3.2.1. Antibiotic Consumption
      • 3.3.2.2. Age and Pregnancy
        • 3.3.2.2.1. Mode of Childbirth
        • 3.3.2.2.2. Type of Feeding
        • 3.3.2.2.3. Antibiotic Consumption by Mother
      • 3.3.2.3. Stress-related Factors
      • 3.3.2.4. Dietary Factors
      • 3.3.2.5. Impact of Lifestyle
  • 3.4. Microbiome and Associated Diseases
    • 3.4.1. Cancer
    • 3.4.2. Inflammatory Bowel Disease (IBD)
    • 3.4.3. Obesity
    • 3.4.4. Parkinson's Disease
    • 3.4.5. Type 2 Diabetes
    • 3.4.6. Other Disease Indications
  • 3.5. Impact of Microbiota on Drug Pharmacokinetics
  • 3.6. Impact of Microbiota on Therapeutic Outcomes
  • 3.7. Microbiome Therapeutics
    • 3.7.1. Probiotics
      • 3.7.1.1. Beneficial Bacterial Strains
        • 3.7.1.1.1. Lactobacilli
        • 3.7.1.1.2. Bifidobacteria
        • 3.7.1.1.3. Others
      • 3.7.1.2. Key Therapeutic Areas
        • 3.7.1.2.1. Antibiotic-Associated Diarrhea (AAD)
        • 3.7.1.2.2. Bacterial Vaginosis
        • 3.7.1.2.3. High Blood Pressure
        • 3.7.1.2.4. Hypercholesterolemia
        • 3.7.1.2.5. Infectious Childhood Diarrhea (ICD)
        • 3.7.1.2.6. Inflammatory Bowel Disease (IBD)
        • 3.7.1.2.7. Lactose Intolerance
        • 3.7.1.2.8. Vitamin Production
        • 3.7.1.2.9. Weight Management
      • 3.7.1.3. Side Effects of Probiotics
    • 3.7.2. Prebiotics
      • 3.7.2.1. Sources of Prebiotics
      • 3.7.2.2. Types of Prebiotics
        • 3.7.2.2.1. Fructo-Oligosaccharides (FOS)
        • 3.7.2.2.2. Galacto-Oligosaccharides (GOS)
        • 3.7.2.2.3. Inulin
      • 3.7.2.3. Key Therapeutic Areas
        • 3.7.2.3.1. Antibiotic Associated Diarrhea (AAD)
        • 3.7.2.3.2. Constipation
        • 3.7.2.3.3. Gastrointestinal Diseases
        • 3.7.2.3.4. Dysbiosis
      • 3.7.2.4. Side Effects of Prebiotics
  • 3.8. The Human Microbiome Project (HMP)
    • 3.8.1. Project Approach
    • 3.8.2. Project Initiatives
    • 3.8.3. Project Achievements
  • 3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)
  • 3.10. Key Challenges Associated with the Development of Microbiome Therapeutics
  • 3.11. Future Perspectives

4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Microbiome Therapeutics: Clinical Pipeline
    • 4.2.1. Analysis by Phase of Development
    • 4.2.2. Analysis by Type of Molecule
    • 4.2.3. Analysis by Phase of Development and Type of Molecule
    • 4.2.4. Analysis by Type of Biologic
    • 4.2.5. Analysis by Type of Product
    • 4.2.6. Analysis by Target Indication
    • 4.2.7. Analysis by Therapeutic Area
    • 4.2.8. Analysis by Route of Administration
    • 4.2.9. Analysis by Type of Formulation
    • 4.2.10. Analysis by Dose Frequency
    • 4.2.11. Analysis by Type of Therapy
    • 4.2.12. Analysis by Combination Drug
  • 4.3. Microbiome Therapeutics: Preclinical Pipeline
    • 4.3.1. Analysis by Phase of Development
    • 4.3.2. Analysis by Type of Molecule
    • 4.3.3. Analysis by Phase of Development and Type of Molecule
    • 4.3.4. Analysis by Type of Biologic
    • 4.3.5. Analysis by Type of Product
    • 4.3.6. Analysis by Target Indication
    • 4.3.7. Analysis by Therapeutic Area
    • 4.3.8. Analysis by Route of Administration
  • 4.4. Microbiome Therapeutics: List of Drug Developers
    • 4.4.1. Analysis by Year of Establishment
    • 4.4.2. Analysis by Company Size
    • 4.4.3. Analysis by Location of Headquarters
    • 4.4.4. Analysis by Company Size and Location of Headquarters

5. MICROBIOME THERAPEUTICS: COMPANY AND DRUG PROFILES

  • 5.1. Chapter Overview
  • 5.2. Microbiome Therapeutics Developers: Companies with Candidate(s) in Highest Phase of Development
  • 5.3. Finch Therapeutics
    • 5.3.1. Company Overview
    • 5.3.2. Microbiome-Based Product Portfolio
      • 5.3.2.1. CP101
        • 5.3.2.1.1. Drug Overview
        • 5.3.2.1.2. Current Status of Development
        • 5.3.2.1.3. Clinical Studies
    • 5.3.3. Recent Developments and Future Outlook
  • 5.4. Infant Bacterial Therapeutics
    • 5.4.1. Company Overview
    • 5.4.2. Microbiome-Based Product Portfolio
      • 5.4.2.1. IBP-9414
        • 5.4.2.1.1. Drug Overview
        • 5.4.2.1.2. Current Status of Development
        • 5.4.2.1.3. Clinical Studies
    • 5.4.3. Recent Developments and Future Outlook
  • 5.5. MaaT Pharma
    • 5.5.1. Company Overview
    • 5.5.2. Microbiome-Based Product Portfolio
      • 5.5.2.1. MaaT013
        • 5.5.2.1.1. Drug Overview
        • 5.5.2.1.2. Current Status of Development
        • 5.5.2.1.3. Clinical Studies
    • 5.5.3. Recent Developments and Future Outlook
  • 5.6. OxThera
    • 5.6.1. Company Overview
    • 5.6.2. Microbiome-Based Product Portfolio
      • 5.6.2.1. Oxabact
        • 5.6.2.1.1. Drug Overview
        • 5.6.2.1.2. Current Status of Development
        • 5.6.2.1.3. Clinical Studies
    • 5.6.3. Recent Developments and Future Outlook
  • 5.7. Rebiotix (acquired by Ferring Pharmaceuticals)
    • 5.7.1. Company Overview
    • 5.7.2. Financial Information
    • 5.7.3. Microbiome-Based Product Portfolio
      • 5.7.3.1. RBX2660
        • 5.7.3.1.1. Drug Overview
        • 5.7.3.1.2. Current Status of Development
        • 5.7.3.1.3. Clinical Studies
    • 5.7.4. Recent Developments and Future Outlook
  • 5.8. Seres Therapeutics
    • 5.8.1. Company Overview
    • 5.8.2. Financial Information
    • 5.8.3. Microbiome-Based Product Portfolio
      • 5.8.3.1. SER-109
        • 5.8.3.1.1. Drug Overview
        • 5.8.3.1.2. Current Status of Development
        • 5.8.3.1.3. Clinical Studies
        • 5.8.3.1.4. Clinical Trial End-Point Analysis
  • 5.9. Microbiome Therapeutics Developers: Companies with Maximum Number of Therapeutic Programs
  • 5.10. 4D Pharma
    • 5.10.1. Company Overview
    • 5.10.2. Financial Information
    • 5.10.3. Microbiome-based Drug Portfolio
    • 5.10.4. Recent Developments and Future Outlook
  • 5.11. Biosortia Pharmaceuticals
    • 5.11.1. Company Overview
    • 5.11.2. Microbiome-based Drug Portfolio
    • 5.11.3. Recent Developments and Future Outlook
  • 5.12. Qu Biologics
    • 5.12.1. Company Overview
    • 5.12.2. Microbiome-based Drug Portfolio
    • 5.12.3. Recent Developments and Future Outlook
  • 5.13. Servatus
    • 5.13.1. Company Overview
    • 5.13.2. Microbiome-based Drug Portfolio
    • 5.13.3. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS: HUMAN MICROBIOME THERAPEUTICS

  • 6.1. Chapter Overview
  • 6.2. Human Microbiome Therapeutics: List of Clinical Trials
    • 6.2.1. Analysis by Trial Status
    • 6.2.2. Analysis by Trial Registration Year
    • 6.2.3. Analysis by Trial Registration Year and Type of Study
    • 6.2.4. Analysis by Trial Phase and Trial Status
    • 6.2.5. Year-wise Trend of Completed and Recruiting Trials
    • 6.2.6. Analysis by Study Design
    • 6.2.7. Analysis by Patient Enrollment
    • 6.2.8. Analysis by Age Category
    • 6.2.9. Analysis by Type of Sponsor / Collaborator
    • 6.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
    • 6.2.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
    • 6.2.12. Analysis by Trial Location
    • 6.2.13. Analysis by Trial Status and Geography

7. MICROBIOME DIAGNOSTICS AND SCREENING / PROFILING TESTS: MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Overview of Microbiome Diagnostics and Screening / Profiling Tests
  • 7.3. Microbiome Diagnostics and Screening / Profiling Tests: Marketed and Under Development Products
    • 7.3.1. Analysis by Stage of Development
    • 7.3.2. Analysis by Type of Test
    • 7.3.3. Analysis by Stage of Development and Type of Test
    • 7.3.4. Analysis by Type of Sample Analyzed
    • 7.3.5. Analysis by Type of Screening Technique
    • 7.3.6. Analysis by Target Indication
    • 7.3.7. Analysis by Therapeutic Area
    • 7.3.8. Analysis by Purpose of Test
  • 7.4. Microbiome Diagnostic and Screening / Profiling Tests Providers
    • 7.4.1. Analysis by Year of Establishment
    • 7.4.2. Analysis by Company Size
    • 7.4.3. Analysis by Location of Headquarters
    • 7.4.4. Analysis by Company Size and Location of Headquarters

8. MICROBIOME DIAGNOSTIC AND SCREENING / PROFILING TEST PROVIDERS: COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. Shoreline Biome
    • 8.2.1. Company Overview
    • 8.2.2. Microbiome Test Portfolio
    • 8.2.3. Recent Developments and Future Outlook
  • 8.3. DNA Genotek
    • 8.3.1. Company Overview
    • 8.3.2. Microbiome Test Portfolio
    • 8.3.3. Recent Developments and Future Outlook
  • 8.4. Invivo Healthcare
    • 8.4.1. Company Overview
    • 8.4.2. Microbiome Test Portfolio
    • 8.4.3. Recent Developments and Future Outlook
  • 8.5. GoodGut
    • 8.5.1. Company Overview
    • 8.5.2. Microbiome Test Portfolio
    • 8.5.3. Recent Developments and Future Outlook
  • 8.6. BiomeDx
    • 8.6.1. Company Overview
    • 8.6.2. Microbiome Test Portfolio
    • 8.6.3. Recent Developments and Future Outlook

9. FECAL MICROBIOTA THERAPY (FMT)

  • 9.1. Chapter Overview
  • 9.2. Introduction to Fecal Microbiota Therapies (FMT)
  • 9.3. Historical Overview
  • 9.4. Fecal Microbiota Therapies: Procedure and Clinical Relevance
    • 9.4.1. Donor Selection
    • 9.4.2. Administration Procedure
    • 9.4.3. Routes of Administration
    • 9.4.4. Consequences and Adverse Events
    • 9.4.5. Clinical Guidelines Associated with FMT
  • 9.5. Regulatory Guidelines Related to Fecal Microbiota Therapies
  • 9.6. Insurance Coverage for Fecal Microbiota Therapies
  • 9.7. Fecal Microbiota Therapies: Marketed and Development Pipeline
    • 9.7.1. Analysis by Application Area
    • 9.7.2. Analysis by Status of Development
    • 9.7.3. Analysis by Target Indication
    • 9.7.4. Analysis by Therapeutic Area
    • 9.7.5. Analysis by Route of Administration
    • 9.7.6. Fecal Microbiota Therapies: List of Developers
      • 9.7.6.1. Analysis by Year of Establishment
      • 9.7.6.2. Analysis by Company Size
      • 9.7.6.3. Analysis by Location of Headquarters

10. CLINICAL TRIALS ANALYSIS: FECAL MICROBIOTA THERAPY

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Fecal Microbiota Therapies: Clinical Trial Analysis
    • 10.3.1. Analysis by Trial Status
    • 10.3.2. Analysis by Trial Registration Year
    • 10.3.3. Analysis by Trial Recruitment Status
    • 10.3.4. Analysis by Trial Phase and Number of Patients Enrolled
    • 10.3.5. Analysis by Study Design
    • 10.3.6. Leading Industry Players: Analysis by Number of Registered Trials
    • 10.3.7. Leading Non-industry Players: Analysis by Number of Registered Trials
    • 10.3.8. Analysis by Trial Location
    • 10.3.9. Analysis by Trial Status and Geography

11. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX

  • 11.1. Chapter Overview
  • 11.2. AC Matrix: An Overview
    • 11.2.1. Strong Business Units
    • 11.2.2. Average Business Units
    • 11.2.3. Weak Business Units
  • 11.3. AC Matrix: Analytical Methodology
  • 11.4. AC Matrix: Plotting the Information
  • 11.5. AC Matrix: Analyzing the Data
    • 11.5.1. Strong Business Units
    • 11.5.2. Average Business Units
    • 11.5.3. Weak Business Units
  • 11.6. Concluding Remarks

12. MICROBIOME RELATED INITIATIVES OF BIG PHARMA PLAYERS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. Initiatives of Big Pharma Players
    • 12.3.1. Analysis by Portfolio Diversity
    • 12.3.2. Analysis by Phase of Development
    • 12.3.3. Analysis by Type of Molecule
    • 12.3.4. Analysis by Type of Therapy
    • 12.3.5. Analysis by Diversity of Therapeutic Areas
  • 12.4. Benchmarking Analysis of Big Pharma Players
    • 12.4.1. Spider Web Analysis: Company A
    • 12.4.2. Spider Web Analysis: Company B
    • 12.4.3. Spider Web Analysis: Company C
    • 12.4.4. Spider Web Analysis: Company D
    • 12.4.5. Spider Web Analysis: Company E
    • 12.4.6. Spider Web Analysis: Company F
    • 12.4.7. Spider Web Analysis: Company G
    • 12.4.8. Spider Web Analysis: Company H
    • 12.4.9. Spider Web Analysis: Company I
    • 12.4.10. Spider Web Analysis: Company J
    • 12.4.11. Spider Web Analysis: Company K

13. START-UP HEALTH INDEXING

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. Benchmarking of Start-ups
    • 13.3.1. Analysis by Portfolio Diversity
    • 13.3.2. Analysis by Phase of Development
    • 13.3.3. Analysis by Diversity in Indication
    • 13.3.4. Analysis by Funding Amount
    • 13.3.5. Analysis by Partnership Activity
    • 13.3.6. Start-up Health Indexing: Roots Analysis Perspective
    • 13.3.7. Start-up Health Indexing: Top Five Start-ups

14. KEY THERAPEUTIC AREAS

  • 14.1. Chapter Overview
  • 14.2. Metabolic Disorders
    • 14.2.1. Diabetes
      • 14.2.1.1. Disease Description
      • 14.2.1.2. Associated Health Risks / Complications
      • 14.2.1.3. Epidemiology
      • 14.2.1.4. Disease Diagnosis
      • 14.2.1.5. Current Treatment Options
        • 14.2.1.5.1. Insulin Therapies
        • 14.2.1.5.2. Non-Insulin Therapies
      • 14.2.1.6. Side Effects of Current Treatment Options
      • 14.2.1.7. Microbiome Therapeutics for Diabetes
    • 14.2.2. Lactose Intolerance
      • 14.2.2.1. Disease Description
      • 14.2.2.2. Epidemiology
      • 14.2.2.3. Current Treatment Options
      • 14.2.2.4. Microbiome Therapeutics for Lactose Intolerance
    • 14.2.3. Nonalcoholic Steatohepatitis (NASH)
      • 14.2.3.1. Disease Description
      • 14.2.3.2. Epidemiology
      • 14.2.3.3. Current Treatment Options
      • 14.2.3.4. Microbiome Therapeutics for NASH
    • 14.2.4. Primary Hyperoxaluria
      • 14.2.4.1. Disease Description
      • 14.2.4.2. Epidemiology
      • 14.2.4.3. Current Treatment Options
      • 14.2.4.4. Microbiome Therapeutics for Primary Hyperoxaluria
    • 14.2.5. Obesity
      • 14.2.5.1. Disease Description
      • 14.2.5.2. Epidemiology
      • 14.2.5.3. Current Treatment Options
      • 14.2.5.4. Side Effects of Current Treatment Options
      • 14.2.5.5. Microbiome Therapeutics for Obesity
  • 14.3. Digestive and Gastrointestinal Disorders
    • 14.3.1. Crohn's Disease
      • 14.3.1.1. Disease Description
      • 14.3.1.2. Epidemiology
      • 14.3.1.3. Current Treatment Options
      • 14.3.1.4. Side Effects of Current Treatment Options
      • 14.3.1.5. Microbiome Therapeutics for Crohn's Disease
    • 14.3.2. Irritable Bowel Syndrome (IBS)
      • 14.3.2.1. Disease Description
      • 14.3.2.2. Epidemiology
      • 14.3.2.3. Current Treatment Options
      • 14.3.2.4. Microbiome Therapeutics for IBS
    • 14.3.3. Ulcerative Colitis
      • 14.3.3.1. Disease Description
      • 14.3.3.2. Epidemiology
      • 14.3.3.3. Current Treatment Options
      • 14.3.3.4. Side Effects of Current Treatment Options
      • 14.3.3.5. Microbiome Therapeutics for Ulcerative Colitis
  • 14.4. Oncological Indications
    • 14.4.1. Colorectal Cancer
      • 14.4.1.1. Disease Description
      • 14.4.1.2. Epidemiology
      • 14.4.1.3. Current Treatment Options
      • 14.4.1.4. Side Effects of Current Treatments
      • 14.4.1.5. Microbiome Therapeutics for Colorectal Cancer
    • 14.4.2. Lung Cancer
      • 14.4.2.1. Disease Description
      • 14.4.2.2. Epidemiology
      • 14.4.2.3. Current Treatment Options
      • 14.4.2.4. Side Effects of Current Treatment Options
      • 14.4.2.5. Microbiome Therapeutics for Lung Cancer
  • 14.5. Dermatological Disorders
    • 14.5.1. Acne Vulgaris
      • 14.5.1.1. Disease Description
      • 14.5.1.2. Epidemiology
      • 14.5.1.3. Current Treatment Options
      • 14.5.1.4. Side Effects of Current Treatment Options
      • 14.5.1.5. Microbiome Therapeutics for Acne Vulgaris
  • 14.6. Infectious Diseases
    • 14.6.1. Clostridium Difficile Infections (CDIs)
      • 14.6.1.1. Disease Description
      • 14.6.1.2. Epidemiology
      • 14.6.1.3. Disease Diagnosis
      • 14.6.1.4. Current Treatment Options
      • 14.6.1.5. Side Effects of Current Treatment Options
      • 14.6.1.6. Microbiome Therapeutics for CDI
    • 14.6.2. Bacterial Vaginosis
      • 14.6.2.1. Disease Description
      • 14.6.2.2. Epidemiology
      • 14.6.2.3. Current Treatment Options
      • 14.6.2.4. Side Effects of Current Treatment Options
      • 14.6.2.5. Microbiome Therapeutics for Bacterial Vaginosis

15. PARTNERSHIPS AND COLLABORATIONS

  • 15.1. Chapter Overview
  • 15.2. Partnership Models
  • 15.3. Human Microbiome: List of Partnerships and Collaborations
  • 15.4. Analysis by Year of Partnership
  • 15.5. Analysis by Type of Partnership
  • 15.6. Analysis by Year and Type of Partnership
  • 15.7. Analysis by Type of Product
  • 15.8. Analysis by Target Indication
  • 15.9. Analysis by Therapeutic Area
  • 15.10. Analysis by Type of Company
  • 15.11. Analysis by Type of Partner
  • 15.12. Most Active Players: Analysis by Number of Partnerships
  • 15.13. Intercontinental and Intracontinental Agreements

16. FUNDING AND INVESTMENT ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Types of Funding
  • 16.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments
    • 16.3.1. Analysis by Year of Investment
    • 16.3.2. Analysis by Amount Invested
    • 16.3.3. Analysis by Type of Funding
    • 16.3.4. Analysis by Type of Company
    • 16.3.5. Analysis by Purpose of Funding
    • 16.3.6. Analysis by Type of Product
    • 16.3.7. Analysis by Target Indication
    • 16.3.8. Analysis by Therapeutic Area
    • 16.3.9. Analysis by Geography
    • 16.3.10. Most Active Players: Analysis by Number of Instances
    • 16.3.11. Most Active Players: Analysis by Amount Invested
    • 16.3.12. Most Active Investors: Analysis by Number of Instances
    • 16.3.13. Funding and Investment Summary

17. CASE STUDY: CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS AND LIVE BIOTHERAPEUTICS

  • 17.1. Chapter Overview
  • 17.2. Manufacturing Microbiome Therapeutics
    • 17.2.1. Key Steps Involved
    • 17.2.2. Associated Challenges
    • 17.2.3. Growing Demand for Contract Manufacturing Services
    • 17.2.4. Contract Manufacturing Organizations (CMOs)
      • 17.2.4.1. Introduction to Contract Manufacturing
    • 17.2.5. Microbiome Therapeutics: List of Contract Manufacturing Providers
      • 17.2.5.1. Analysis by Year of Establishment
      • 17.2.5.2. Analysis by Company Size
      • 17.2.5.3. Analysis by Location of Headquarters
      • 17.2.5.4. Analysis by Scale of Operation
      • 17.2.5.5. Analysis by Type of Product Manufactured
      • 17.2.5.6. Analysis by Type of Formulation
      • 17.2.5.7. Analysis by Scale of Operation and Type of Formulation
  • 17.3. Key Considerations for Selecting a CMO / CRO Partner

18. BIG DATA AND MICROBIOME THERAPEUTICS

  • 18.1. Chapter Overview
  • 18.2. Introduction to Big Data
  • 18.3. Internet of Things (IoT)
  • 18.4. Growing Interest in Big Data: Google Trends Analysis
  • 18.5. Key Application Areas
  • 18.6. Big Data in Microbiome Research
    • 18.6.1. Microbiome Data and Personalized Medicine
    • 18.6.2. Microbiome-related Data Management Challenges
    • 18.6.3. National Microbiome Data Center
  • 18.7. Big Data Services for Microbiome Research: List of Companies
  • 18.8. Big Data Services for Microbiome Research: Profiles of Key Players
    • 18.8.1. Human Longevity
      • 18.8.1.1. Company Overview
      • 18.8.1.2. Technology and Service Portfolio
      • 18.8.1.3. Recent Developments and Future Outlook
    • 18.8.2. Resilient Biotics
      • 18.8.2.1. Company Overview
      • 18.8.2.2. Technology and Service Portfolio
      • 18.8.2.3. Recent Developments and Future Outlook
    • 18.8.3. Resphera Biosciences
      • 18.8.3.1. Company Overview
      • 18.8.3.2. Technology and Service Portfolio
      • 18.8.3.3. Recent Developments and Future Outlook

19. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions
  • 19.3. Forecast Methodology
  • 19.4. Global Microbiome Therapeutics Market, Till 2035
    • 19.4.1. Microbiome Therapeutics Market: Distribution by Type of Product Till 2035
      • 19.4.1.1. Microbiome Therapeutics Market for Probiotic Drugs, Till 2035
      • 19.4.1.2. Microbiome Therapeutics Market for Other Drugs, Till 2035
    • 19.4.2. Microbiome Therapeutics Market: Distribution by Target Disease Indication, Till 2035
      • 19.4.2.1. Microbiome Therapeutics Market for Graft Versus Host Disease, Till 2035
      • 19.4.2.2. Microbiome Therapeutics Market for Necrotizing Enterocolitis, Till 2035
      • 19.4.2.3. Microbiome Therapeutics Market for Primary Hyperoxaluria, Till 2035
      • 19.4.2.4. Microbiome Therapeutics Market for Recurrent C. difficile Infection, Till 2035
    • 19.4.3. Microbiome Therapeutics Market: Distribution by Therapeutic Area, Till 2035
      • 19.4.3.1. Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, Till 2035
      • 19.4.3.2. Microbiome Therapeutics Market for Infectious Diseases, Till 2035
      • 19.4.3.3. Microbiome Therapeutics Market for Rare Disorders, Till 2035
    • 19.4.4. Microbiome Therapeutics Market: Route of Administration, Till 2035
      • 19.4.4.1. Microbiome Therapeutics Market for Oral Therapeutics, Till 2035
      • 19.4.4.2. Microbiome Therapeutics Market for Rectal Therapeutics, Till 2035
    • 19.4.5. Microbiome Therapeutics Market: Distribution by Type of Formulation, Till 2035
      • 19.4.5.1. Microbiome Therapeutics Market for Capsules, Till 2035
      • 19.4.5.2. Microbiome Therapeutics Market for Suspensions, Till 2035
      • 19.4.5.3. Microbiome Therapeutics Market for Enemas, Till 2035
    • 19.4.6. Microbiome Therapeutics Market: Distribution by Key Geographical Regions, Till 2035
      • 19.4.6.1. Microbiome Therapeutics Market in North America, Till 2035
      • 19.4.6.2. Microbiome Therapeutics Market in Europe, Till 2035
      • 19.4.6.3. Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, Till 2035
    • 19.4.7. Microbiome Therapeutics Market: Distribution by Leading Drug Developers, Till 2035
    • 19.4.8. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, Till 2035
      • 19.4.8.1. SER-109 (Seres Therapeutics)
      • 19.4.8.2. RBX2660 (ReBiotix)
      • 19.4.8.3. CP101 (Finch Therapeutics)
      • 19.4.8.4. IBP-9414 (Infant bacterial Therapeutics)
      • 19.4.8.5. Oxabact (OxThera)
      • 19.4.8.6. MaaT013 (MaaT Pharma)

20. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 20.1. Chapter Overview
  • 20.2. Scope and Limitations
  • 20.3. Forecast Methodology
  • 20.4. Global Human Microbiome Diagnostic Test Market, Till 2035
    • 20.4.1. Human Microbiome Diagnostic Tests Market by Target Indication
      • 20.4.1.1. Human Microbiome Diagnostic Tests Market for Inflammatory Bowel Syndrome, Till 2035
      • 20.4.1.2. Human Microbiome Diagnostic Tests Market for Irritable Bowel Disease, Till 2035
      • 20.4.1.3. Human Microbiome Diagnostic Tests Market for Colorectal Cancer, Till 2035
      • 20.4.1.4. Human Microbiome Diagnostic Tests Market for Diabetes Mellitus, Till 2035
    • 20.4.2. Human Microbiome Diagnostic Tests Market: Distribution by Therapeutic Area
      • 20.4.2.1. Human Microbiome Diagnostic Tests Market for Digestive and Gastrointestinal Disorders, Till 2035
      • 20.4.2.2. Human Microbiome Diagnostic Tests Market for Oncological Disorders, Till 2035
      • 20.4.2.3. Human Microbiome Diagnostic Tests Market for Metabolic Disorders, Till 2035
    • 20.4.3. Human Microbiome Diagnostic Tests Market: Distribution by Key Geographical Regions
      • 20.4.3.1. Human Microbiome Diagnostic Tests Market in North America, Till 2035
      • 20.4.3.2. Human Microbiome Diagnostic Tests Market in Europe, Till 2035
      • 20.4.3.3. Human Microbiome Diagnostic Tests Market in Asia Pacific, Till 2035

21. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 21.1. Chapter Overview
  • 21.2. Forecast Methodology and Key Assumptions
  • 21.3. Global Fecal Microbiota Therapies Market, Till 2035
    • 21.3.1. Global Fecal Microbiota Therapies Market, Till 2035 (By Value)
    • 21.3.2. Global Fecal Microbiota Therapies Market, Till 2035 (By Value)
    • 21.3.3. Overall FMT Market, Till 2035 (By Volume)
  • 21.4. Overall Microbiome Market by Product Offerings, Till 2035

22. CASE STUDY: MICROBIOME-BASED PRODUCTS IN NON-PHARMACEUTICAL INDUSTRIES

  • 22.1. Chapter Overview
  • 22.2. List of Microbiome Products in Non-Pharmaceutical Industry
    • 22.2.1. Applications of Microbiome Based Products in Cosmetics and Food Industry
  • 22.3. Applications of Microbiome Based Products in Agriculture Industry
  • 22.4. Future Perspectives

23. CONCLUDING REMARKS

24. EXECUTIVE INSIGHTS

  • 24.1. Chapter Overview
  • 24.2. Company A
    • 24.2.1. Company / Organization Snapshot
    • 24.2.2. Interview Transcript: Senior Manager, Corporate Development
  • 24.3. Company B
    • 24.3.1. Company / Organization Snapshot
    • 24.3.2. Interview Transcript: Co-founder and Chairman
  • 24.4. Company C
    • 24.4.1. Company / Organization Snapshot
    • 24.4.2. Interview Transcript: Chief Executive Officer
  • 24.5. Company D
    • 24.5.1. Company / Organization Snapshot
    • 24.5.2. Interview Transcript: Senior Scientist
  • 24.6. Company E
    • 24.6.1. Company / Organization Snapshot
    • 24.6.2. Interview Transcript: Associate General Manager
  • 24.7. Company F
    • 24.7.1. Company / Organization Snapshot
    • 24.7.2. Interview Transcript: Ex-Vice President, Business Development
  • 24.8. Company G
    • 24.8.1. Company / Organization Snapshot
    • 24.8.2. Interview Transcript: Chief Business Officer
  • 24.9. Company H
    • 24.9.1. Company / Organization Snapshot
    • 24.9.2. Interview Transcript: Ex-Vice President, Sales and Business Development
  • 24.10. Company I
    • 24.10.1. Company / Organization Snapshot
    • 24.10.2. Interview Transcript: Co-founder and Chief Executive Officer
  • 24.11. Company J
    • 24.11.1. Company / Organization Snapshot
    • 24.11.2. Interview Transcript: Co-founder and Chief Executive Officer
  • 24.12. Company K
    • 24.12.1. Company / Organization Snapshot
    • 24.12.2. Interview Transcripts: Co-founder and Chief Executive Officer
  • 24.13. Company L
    • 24.13.1. Company / Organization Snapshot
    • 24.13.2. Interview Transcripts: Ex-Co-founder and Vice President of Innovation
  • 24.14. Company M
    • 24.14.1. Company / Organization Snapshot
    • 24.14.2. Interview Transcript: Vice President, Business Development and Marketing
  • 24.15. Company N
    • 24.15.1. Company / Organization Snapshot
    • 24.15.2. Interview Transcript: Ex-Vice President, Operations
  • 24.16. Company O
    • 24.16.1. Company / Organization Snapshot
    • 24.16.2. Interview Transcript: President and Chief Executive Officer
  • 24.17. Company P
    • 24.17.1. Company / Organization Snapshot
    • 24.17.2. Interview Transcript: Ex-Chief Scientific Officer and Vice President
  • 24.18. Company Q
    • 24.18.1. Company / Organization Snapshot
    • 24.18.2. Interview Transcript: Chief Strategy Officer

25. APPENDIX I: TABULATED DATA

26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Show more
Product Code: RA100346

List of Tables

  • Table 3.1 Types of Microbiota in the Gastrointestinal Tract
  • Table 3.2 Common Instances of Misuse of Antibiotics
  • Table 3.3 Impact of Antibiotics on Intestinal Microflora
  • Table 3.4 List of Microorganisms Classified as Class I Carcinogens by the IARC
  • Table 3.5 Relationship Between Microbiome and Disease Progression
  • Table 3.6 Impact of Drug-Microbiome Interactions
  • Table 3.7 List of Foods Containing Prebiotics
  • Table 4.1 Microbiome Therapeutics: Clinical Pipeline
  • Table 4.2 Clinical Phase Microbiome Therapeutics: Information on Type of Molecule and Route of Administration
  • Table 4.3 Clinical Phase Microbiome Therapeutics: Additional Information
  • Table 4.4 Microbiome Therapeutics: Preclinical Pipeline
  • Table 4.5 Preclinical Phase Microbiome Therapeutics: Additional Information
  • Table 4.6 Microbiome Therapeutics: List of Drug Developers
  • Table 5.1 Microbiome Therapeutic Developers: Companies with Candidates in Highest Phase of Development
  • Table 5.2 Finch Therapeutics: Microbiome-Based Product Portfolio
  • Table 5.3 CP101: Current Status of Development
  • Table 5.4 CP101: Clinical Studies
  • Table 5.5 Finch Therapeutics: Recent Developments and Future Outlook
  • Table 5.6 Infant Bacterial Therapeutics: Microbiome-Based Product Portfolio
  • Table 5.7 IBP-9414: Current Status of Development
  • Table 5.8 IBP-9414: Clinical Studies
  • Table 5.9 Infant Bacterial Therapeutics: Recent Developments and Future Outlook
  • Table 5.10 MaaT Pharma: Microbiome-Based Product Portfolio
  • Table 5.11 MaaT013: Current Status of Development
  • Table 5.12 MaaT013: Clinical Studies
  • Table 5.13 MaaT Pharma: Recent Developments and Future Outlook
  • Table 5.14 OxThera: Microbiome-Based Product Portfolio
  • Table 5.15 Oxabact: Current Status of Development
  • Table 5.16 Oxabact: Clinical Studies
  • Table 5.17 OxThera: Recent Developments and Future Outlook
  • Table 5.18 Rebiotix: Microbiome-Based Product Portfolio
  • Table 5.19 RBX2660: Current Status of Development
  • Table 5.20 RBX2660: Clinical Studies
  • Table 5.21 Rebiotix: Recent Developments and Future Outlook
  • Table 5.22 Seres Therapeutics: Microbiome-Based Product Portfolio
  • Table 5.23 SER-109: Current Status of Development
  • Table 5.24 SER-109: Clinical Studies
  • Table 5.25 Seres Therapeutics: Recent Developments and Future Outlook
  • Table 5.26 Microbiome Therapeutics Developers: Companies with Maximum Number of Therapeutic Programs
  • Table 5.27 4D Pharma: Financial Information
  • Table 5.28 4D Pharma: Recent Developments and Future Outlook
  • Table 5.29 Biosortia Pharmaceuticals: Recent Developments and Future Outlook
  • Table 5.30 Qu Biologics: Recent Developments and Future Outlook
  • Table 5.31 Servatus: Recent Developments and Future Outlook
  • Table 6.1 Microbiome Diagnostics and Screening / Profiling Tests: Marketed and Development Pipeline
  • Table 6.2 Microbiome Diagnostics and Screening / Profiling Tests: List of Developers
  • Table 7.1 Shoreline Biome: Company Overview
  • Table 7.2 Shoreline Biome: Microbiome Test Portfolio
  • Table 7.3 Shoreline Biome: Recent Developments and Future Outlook
  • Table 7.4 DNA Genotek: Company Overview
  • Table 7.5 DNA Genotek: Microbiome Test Portfolio
  • Table 7.6 DNA Genotek: Recent Developments and Future Outlook
  • Table 7.7 Invivo Healthcare: Company Overview
  • Table 7.8 Invivo Healthcare: Microbiome Test Portfolio
  • Table 7.9 Invivo Healthcare: Recent Developments and Future Outlook
  • Table 7.10 GoodGut: Company Overview
  • Table 7.11 GoodGut: Microbiome Test Portfolio
  • Table 7.12 GoodGut: Recent Developments and Future Outlook
  • Table 7.13 BiomeDx: Company Overview
  • Table 7.14 BiomeDx: Microbiome Test Portfolio
  • Table 7.15 BiomeDx: Recent Developments and Future Outlook
  • Table 8.1 Comparison between Various Routes of Administration of FMT
  • Table 8.2 FMT: Summary of Clinical Guidelines
  • Table 8.3 FMT: Summary of Insurance Coverage Payer
  • Table 8.4 FMT: Marketed and Development Pipeline
  • Table 8.5 FMT: List of Developers
  • Table 8.6 List of Stool Banks for FMT Development
  • Table 8.7 Fecal Microbiota Transplant and Human Microbiome Transplant (HMT): Key Differences in Processing
  • Table 8.8 Flora Medicine: Fecal Microbiota Transplant Treatment Cost
  • Table 8.9 OpenBiome: Types of FMT Formulations
  • Table 9.1 Fecal Microbiota Transplant: List of Registered Clinical Trials
  • Table 12.1 Diabetes: Current Treatment Options
  • Table 12.2 Diabetes: Side Effects of Current Treatment Options
  • Table 12.3 Microbiome Therapeutics Candidates for Diabetes
  • Table 12.4 Microbiome Therapeutics Candidates for Lactose Intolerance
  • Table 12.5 Microbiome Therapeutics Candidates for NASH
  • Table 12.6 Microbiome Therapeutics Candidates for Primary Hyperoxaluria
  • Table 12.7 Obesity: Side Effects of Current Treatment Options
  • Table 12.8 Microbiome Therapeutic Candidates for Obesity
  • Table 12.9 Crohn's Disease: Current Treatment Options
  • Table 12.10 Crohn's Disease: Side Effects of Current Treatment Options
  • Table 12.11 Microbiome Therapeutics Candidates for Crohn's Disease
  • Table 12.12 IBS: Current Treatment Options
  • Table 12.13 Microbiome Therapeutics Candidates for IBS
  • Table 12.14 Ulcerative Colitis: Current Treatment Options
  • Table 12.15 Ulcerative Colitis: Side Effects of Current Treatment Options
  • Table 12.16 Microbiome Therapeutics Candidates for Ulcerative Colitis
  • Table 12.17 Colorectal Cancer: Side Effects of Current Treatment Options
  • Table 12.18 Microbiome Therapeutics Pipeline for Colorectal Cancer
  • Table 12.19 Lung Cancer: Current Treatment Options
  • Table 12.20 Lung Cancer: Side Effects of Current Treatment Options
  • Table 12.21 Microbiome Therapeutics Candidates for Lung Cancer
  • Table 12.22 Acne Vulgaris: Current Treatment Options
  • Table 12.23 Acne Vulgaris: Side Effects of Current Treatment Options
  • Table 12.24 Microbiome Therapeutics Candidates for Acne Vulgaris
  • Table 12.25 CDI: Diagnostic Testing
  • Table 12.26 CDI: Severity Scoring System and Treatment Options
  • Table 12.27 CDI: Side Effects of Current Treatment Options
  • Table 12.28 Microbiome Therapeutics Candidates for CDI
  • Table 12.29 Bacterial Vaginosis: Current Treatment Options
  • Table 12.30 Bacterial Vaginosis: Side Effects of Current Treatment Options
  • Table 12.31 Microbiome Therapeutics Candidates for Bacterial Vaginosis
  • Table 13.1 Human Microbiome: List of Partnerships and Collaborations, Since 2017
  • Table 14.1 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Funding Type, Year, Amount and Investor, Since 2017
  • Table 14.2 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Type of Product, Target Indication and Focus Area, Since 2017
  • Table 14.3 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Type of Investor and Location of Headquarters, Since 2017
  • Table 15.1 Microbiome Contract Manufacturers: Information on Year of Establishment, Headquarters, Company Size, Accreditation Received and Scale of Operation
  • Table 15.2 Microbiome Contract Manufacturers: Information on Type of Product Manufactured
  • Table 15.3 Microbiome Contract Manufacturers: Information on Type of Formulation
  • Table 15.4 Comparison of Key Factors for the Selection of Contract Service Providers: Harvey Ball Analysis
  • Table 16.1 List of Companies Using Big Data for Microbiome Research
  • Table 16.2 Human Longevity: Partnerships and Collaborations
  • Table 16.3 Human Longevity: Venture Capital Funding
  • Table 16.4 Resilient Biotics: Venture Capital Funding
  • Table 20.1 List of Companies Engaged in the Development of Microbiome Products for Other Applications
  • Table 20.2 Pipeline of Microbiome Based Consumer Products, Medical Foods and Supplements
  • Table 22.1 Quorum Innovations: Company / Organization Snapshot
  • Table 22.2 Floragraph: Company / Organization Snapshot
  • Table 22.3 Pacific Northwest National Laboratories: Company / Organization Snapshot
  • Table 22.4 Chung Mei Pharmaceutical: Company / Organization Snapshot
  • Table 22.5 Universal Stabilization technologies: Company / Organization Snapshot
  • Table 22.6 BiomX: Company / Organization Snapshot
  • Table 22.7 List Biological Laboratories: Company / Organization Snapshot
  • Table 22.8 S-Biomedic: Company / Organization Snapshot
  • Table 22.9 Pendulum Therapeutics: Company / Organization Snapshot
  • Table 22.10 Siolta Therapeutics: Company / Organization Snapshot
  • Table 22.11 OpenBiome: Company / Organization Snapshot
  • Table 22.12 Metabiomics: Company / Organization Snapshot
  • Table 22.13 Assembly Biosciences: Company / Organization Snapshot
  • Table 22.14 Microbiome Therapeutics: Company / Organization Snapshot
  • Table 22.15 Da Volterra: Company Snapshot
  • Table 23.1 Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development
  • Table 23.2 Clinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
  • Table 23.3 Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
  • Table 23.4 Clinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
  • Table 23.5 Clinical Phase Microbiome Therapeutics: Distribution by Type of Product
  • Table 23.6 Clinical Phase Microbiome Therapeutics: Distribution by Target Indication
  • Table 23.7 Clinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
  • Table 23.8 Clinical Phase Microbiome Therapeutics: Distribution by Route of Administration
  • Table 23.9 Clinical Phase Microbiome Therapeutics: Distribution by Type of Formulation
  • Table 23.10 Clinical Phase Microbiome Therapeutics: Distribution by Dose Frequency
  • Table 23.11 Clinical Phase Microbiome Therapeutics: Distribution by Type of Therapy
  • Table 23.12 Clinical Phase Microbiome Therapeutics: Distribution by Combination Drug
  • Table 23.13 Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development
  • Table 23.14 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
  • Table 23.15 Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
  • Table 23.16 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
  • Table 23.17 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Product
  • Table 23.18 Preclinical Phase Microbiome Therapeutics: Distribution by Target Indication
  • Table 23.19 Preclinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
  • Table 23.20 Microbiome Therapeutic Developers: Distribution by Year of Establishment
  • Table 23.21 Microbiome Therapeutic Developers: Distribution by Company Size
  • Table 23.22 Microbiome Therapeutic Developers: Distribution by Location of Headquarters
  • Table 23.23 Seres Therapeutics: Financial Information, Since 2017 (USD Million)
  • Table 23.24 4D Pharma: Financial Information, Since 2017 (USD Million)
  • Table 23.25 Ferring Pharmaceuticals: Financial Information, Since 2019 (USD Million)
  • Table 23.26 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development
  • Table 23.27 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Test
  • Table 23.28 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development and Type of Test
  • Table 23.29 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Sample Analyzed
  • Table 23.30 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Screening Technique
  • Table 23.31 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Target Indication
  • Table 23.32 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Therapeutic Area
  • Table 23.33 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Purpose of Test
  • Table 23.34 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Year of Establishment
  • Table 23.35 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Company Size
  • Table 23.36 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Location of Headquarters
  • Table 23.37 Most Active Microbiome Test Providers: Distribution by Number of Microbiome Tests
  • Table 23.38 Fecal Microbiota Transplantation: Distribution by Application Area
  • Table 23.39 Fecal Microbiota Transplantation: Distribution by Status of Development
  • Table 23.40 Fecal Microbiota Transplantation: Distribution by Target Indication
  • Table 23.41 Fecal Microbiota Transplantation: Distribution by Therapeutic Area
  • Table 23.42 Fecal Microbiota Transplantation: Distribution by Route of Administration
  • Table 23.43 Fecal Microbiota Transplantation Developers: Distribution by Year of Establishment
  • Table 23.44 Fecal Microbiota Transplantation Developers: Distribution by Company Size
  • Table 23.45 Fecal Microbiota Transplantation Developers: Distribution by Location of Headquarters
  • Table 23.46 Clinical Trial Analysis: Distribution by Trial Status
  • Table 23.47 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since Pre 2015
  • Table 23.48 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since Pre 2015
  • Table 23.49 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
  • Table 23.50 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
  • Table 23.51 Clinical Trial Analysis: Distribution by Study Design
  • Table 23.52 Leading Industry Players: Distribution by Number of Registered Trials
  • Table 23.53 Leading Non-industry Players: Distribution by Number of Registered Trials\
  • Table 23.54 Clinical Trial Analysis: Analysis by Trial Location
  • Table 23.55 Clinical Trial Analysis: Analysis by Trial Status and Geography
  • Table 23.56 Benchmarking of Start-ups: Distribution by Portfolio Diversity
  • Table 23.57 Benchmarking of Start-ups: Distribution by Phase of Development
  • Table 23.58 Benchmarking of Start-ups: Distribution by Indication Diversity
  • Table 23.59 Benchmarking of Start-ups: Distribution by Funding Amount
  • Table 23.60 Benchmarking of Start-ups: Distribution by Partnership Activity
  • Table 23.61 Partnerships and Collaborations: Distribution of Cumulative Year-wise Trend, Since 2017
  • Table 23.62 Partnerships and Collaborations: Distribution of Type of Partnership
  • Table 23.63 Partnerships and Collaborations: Distribution of Year and Type of Partnership, Since 2017
  • Table 23.64 Partnerships and Collaborations: Distribution of Type of Collaborator
  • Table 23.65 Partnerships and Collaborations: Distribution of Target Indication
  • Table 23.66 Partnerships and Collaborations: Distribution by Type of Partnership and Target Indication
  • Table 23.67 Partnerships and Collaborations: Distribution of Therapeutic Area
  • Table 23.68 Most Active Players: Distribution by Number of Partnerships
  • Table 23.69 Partnerships and Collaborations: Distribution by Type of Agreement (Country wise)
  • Table 23.70 Partnerships and Collaborations: Distribution by Type of Agreement (Region wise)
  • Table 23.71 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 23.72 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, Since 2017
  • Table 23.73 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested (USD Million), Since 2017
  • Table 23.74 Funding and Investment Analysis: Distribution by Type of Funding
  • Table 23.75 Funding and Investment Analysis: Distribution by Year and Type of Funding
  • Table 23.76 Funding and Investment Analysis: Distribution by Type of Funding and Amount Invested (USD Million)
  • Table 23.77 Funding and Investment Analysis: Distribution by Purpose of Funding
  • Table 23.78 Funding and Investment Analysis: Distribution by Type of Product
  • Table 23.79 Funding and Investment Analysis: Distribution by Target Indication
  • Table 23.80 Funding and Investment Analysis: Distribution by Therapeutic Area
  • Table 23.81 Funding and Investment Analysis: Distribution by Type of Product, Type of Funding and Amount Invested (USD Million)
  • Table 23.82 Funding and Investment Analysis: Distribution by Region
  • Table 23.83 Most Active Players: Distribution by Number of Instances
  • Table 23.84 Most Active Players: Distribution by Amount Raised (USD Million)
  • Table 23.85 Key Investors: Distribution by Number of Funding Instances
  • Table 23.86 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Year of Establishment
  • Table 23.87 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Company Size
  • Table 23.88 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Headquarters
  • Table 23.89 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation
  • Table 23.90 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Product Manufactured
  • Table 23.91 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation
  • Table 23.92 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
  • Table 23.93 Global Human Microbiome Therapeutics Market, Till 2035 (USD Billion)
  • Table 23.94 Human Microbiome Therapeutics Market: Distribution by Type of Product (USD Million)
  • Table 23.95 Human Microbiome Therapeutics Market for Probiotic Drugs, Till 2035 (USD Million)
  • Table 23.96 Human Microbiome Therapeutics Market for Other Drugs, Till 2035 (USD Million)
  • Table 23.97 Human Microbiome Therapeutics Market: Distribution by Target Disease Indication
  • Table 23.98 Human Microbiome Therapeutics Market for Recurrent C. difficile Infection, Till 2035 (USD Million)
  • Table 23.99 Human Microbiome Therapeutics Market for Necrotizing Enterocolitis, Till 2035 (USD Million)
  • Table 23.100 Human Microbiome Therapeutics Market for Primary Hyperoxaluria, Till 2035 (USD Million)
  • Table 23.101 Human Microbiome Therapeutics Market for Graft versus Host Disease, Till 2035 (USD Million)
  • Table 23.102 Human Microbiome Therapeutics Market: Distribution by Therapeutic Area (USD Million)
  • Table 23.103 Human Microbiome Therapeutics Market for Infectious Diseases, Till 2035 (USD Million)
  • Table 23.104 Human Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, Till 2035 (USD Million)
  • Table 23.105 Human Microbiome Therapeutics Market for Rare Disorders, Till 2035 (USD Million)
  • Table 23.106 Human Microbiome Therapeutics Market: Distribution by Route of Administration (USD Million)
  • Table 23.107 Human Microbiome Therapeutics Market for Oral Therapeutics, Till 2035 (USD Million)
  • Table 23.108 Human Microbiome Therapeutics Market for Rectal Therapeutics, Till 2035 (USD Million)
  • Table 23.109 Human Microbiome Therapeutics Market: Distribution by Type of Formulation (USD Million)
  • Table 23.110 Human Microbiome Therapeutics Market for Capsules, Till 2035 (USD Million)
  • Table 23.111 Human Microbiome Therapeutics Market for Suspensions, Till 2035 (USD Million)
  • Table 23.112 Human Microbiome Therapeutics Market for Enemas, Till 2035 (USD Million)
  • Table 23.113 Human Microbiome Therapeutics Market: Distribution by Key Geographical Regions, Till 2035 (USD Million)
  • Table 23.114 Human Microbiome Therapeutics Market in North America, Till 2035 (USD Million)
  • Table 23.115 Human Microbiome Therapeutics Market in Europe, Till 2035 (USD Million)
  • Table 23.116 Human Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, Till 2035 (USD Million)
  • Table 23.117 Human Microbiome Therapeutics Market: Distribution by Leading Drug Developers, Till 2035 (USD Million)
  • Table 23.118 Sales Forecast: SER-109, Till 2035 (USD Million)
  • Table 23.119 Sales Forecast: RBX2660, Till 2035 (USD Million)
  • Table 23.120 Sales Forecast: CP101, Till 2035 (USD Million)
  • Table 23.121 Sales Forecast: IBP-9414, Till 2035 (USD Million)
  • Table 23.122 Sales Forecast: Oxabact, Till 2035 (USD Million)
  • Table 23.123 Sales Forecast: MaaT013, Till 2035 (USD Million)
  • Table 23.124 Overall Microbiome Diagnostics Market, Till 2035 (USD Million)
  • Table 23.125 Microbiome Diagnostics Market: Distribution by Target Indications, Till 2035 (USD Million)
  • Table 23.126 Microbiome Diagnostics Market for Irritable Bowel Syndrome, Till 2035 (USD Million)
  • Table 23.127 Microbiome Diagnostics Market for Inflammatory Bowel Disease, Till 2035 (USD Million)
  • Table 23.128 Microbiome Diagnostics Market for Colorectal Cancer, Till 2035 (USD Million)
  • Table 23.129 Microbiome Diagnostics Market for Diabetes Mellitus, Till 2035 (USD Million)
  • Table 23.130 Microbiome Diagnostics Market: Distribution by Therapeutic Areas, Till 2035 (USD Million)
  • Table 23.131 Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, Till 2035 (USD Million)
  • Table 23.132 Microbiome Diagnostics Market for Oncological Disorders, Till 2035 (USD Million)
  • Table 23.133 Microbiome Diagnostics Market for Metabolic Disorders, Till 2035 (USD Million)
  • Table 23.134 Microbiome Diagnostics Market: Distribution by Key Geographical Regions, Till 2035 (USD Million)
  • Table 23.135 Microbiome Diagnostics Market in North America, Till 2035 (USD Million)
  • Table 23.136 Microbiome Diagnostics Market in Europe, Till 2035 (USD Million)
  • Table 23.137 Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, Till 2035 (USD Million)
  • Table 23.138 Global Fecal Microbiota Therapies Market, Till 2035 (USD Million)
  • Table 23.139 Global Microbiota Therapies Market, Till 2035 (Million Procedures)
  • Table 23.140 Fecal Microbiota Therapies Market in North America, Till 2035 (USD Million)
  • Table 23.141 Fecal Microbiota Therapies Market in Europe, Till 2035 (USD Million)
  • Table 23.142 Fecal Microbiota Therapies Market in Asia Pacific, Till 2035 (USD Million)
  • Table 23.143 Fecal Microbiota Therapies Market in North America, Till 2035 (Million Procedures)
  • Table 23.144 Fecal Microbiota Therapies in Europe, Till 2035 (Million Procedures)
  • Table 23.145 Fecal Microbiota Therapies Market in Asia Pacific, Till 2035 (Million Procedures)
  • Table 23.146 Overall Human Microbiome Market: Distribution by Product Offerings (USD Million)

List of Figures

  • Figure 2.1 Executive Summary: Overall Market Landscape of Human Microbiome Therapeutics
  • Figure 2.2 Executive Summary: Overall Market Landscape of Human Microbiome Diagnostics and Screening / Profiling Tests
  • Figure 2.3 Executive Summary: Overall Market Landscape of Fecal Microbiota Therapies and Clinical Trial Analysis
  • Figure 2.4 Executive Summary: Partnerships and Collaborations
  • Figure 2.5 Executive Summary: Funding and Investment Analysis
  • Figure 2.6 Executive Summary: Market Sizing and Opportunity Analysis for Microbiome Therapeutics
  • Figure 2.7 Executive Summary: Market Sizing and Opportunity Analysis for Microbiome Diagnostics and Fecal Microbiota Therapies
  • Figure 3.1 Benefits of the Human Microbiota
  • Figure 3.2 Factors Affecting Gut Microbiota
  • Figure 3.3 Factors Affecting Gut Microbiota in Infants
  • Figure 3.4 Impact of Diet on Gut Microbiota
  • Figure 3.5 Types of Microbiome-Based Therapeutics
  • Figure 3.6 Approaches to Design Microbiome Therapeutics
  • Figure 3.7 Health Benefits of Probiotics
  • Figure 3.8 Mechanism of Action of Probiotics
  • Figure 3.9 Beneficial Bacterial Strains for Probiotics
  • Figure 3.10 Key Achievements of the Human Microbiome Project (HMP)
  • Figure 3.11 Challenges Associated with the Development of Microbiome Therapeutics
  • Figure 4.1 Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development
  • Figure 4.2 Clinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
  • Figure 4.3. Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
  • Figure 4.4 Clinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
  • Figure 4.5 Clinical Phase Microbiome Therapeutics: Distribution by Type of Product
  • Figure 4.6 Clinical Phase Microbiome Therapeutics: Distribution by Target Indication
  • Figure 4.7 Clinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
  • Figure 4.8 Clinical Phase Microbiome Therapeutics: Distribution by Route of Administration
  • Figure 4.9 Clinical Phase Microbiome Therapeutics: Distribution by Type of Formulation
  • Figure 4.10 Clinical Phase Microbiome Therapeutics: Distribution by Dose Frequency
  • Figure 4.11 Clinical Phase Microbiome Therapeutics: Distribution by Type of Therapy
  • Figure 4.12 Clinical Phase Microbiome Therapeutics: Distribution by Combination Drug
  • Figure 4.13 Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development
  • Figure 4.14 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
  • Figure 4.15 Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
  • Figure 4.16 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
  • Figure 4.17 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Product
  • Figure 4.18 Preclinical Phase Microbiome Therapeutics: Distribution by Target Indication
  • Figure 4.19 Preclinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
  • Figure 4.20 Preclinical Phase Microbiome Therapeutics: Distribution by Route of Administration
  • Figure 4.21 Microbiome Therapeutic Developers: Distribution by Year of Establishment
  • Figure 4.22 Microbiome Therapeutic Developers: Distribution by Company Size
  • Figure 4.23 Microbiome Therapeutic Developers: Distribution by Location of Headquarters
  • Figure 4.24 Microbiome Therapeutic Developers: Distribution by Company Size and Location of Headquarters
  • Figure 5.1 Rebiotix: Financial Information, Since 2017 (USD Million)
  • Figure 5.2 Seres Therapeutics: Financial Information, Since 2017 (USD Million)
  • Figure 5.3 4D Pharma: Financial Information, Since 2017 (USD Million)
  • Figure 6.1 Key Steps in 16S rRNA Gene Sequence Analysis
  • Figure 6.2 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development
  • Figure 6.3 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Test
  • Figure 6.4 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development and Type of Test
  • Figure 6.5 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Sample Analyzed
  • Figure 6.6 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Screening Technique
  • Figure 6.7 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Target Indication
  • Figure 6.8 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Therapeutic Area
  • Figure 6.9 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Purpose of Test
  • Figure 6.10 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Year of Establishment
  • Figure 6.11 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Company Size
  • Figure 6.12 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Location of Headquarters
  • Figure 6.13 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Company Size and Location of Headquarters
  • Figure 8.1 Working Mechanism of a Microflora Refinement System
  • Figure 8.2 Fecal Microbiota Therapies: Distribution by Application Area
  • Figure 8.3 Fecal Microbiota Therapies: Distribution by Status of Development
  • Figure 8.4 Fecal Microbiota Therapies: Distribution by Target Indication
  • Figure 8.5 Fecal Microbiota Therapies: Distribution by Therapeutic Area
  • Figure 8.6 Fecal Microbiota Therapies: Distribution by Route of Administration
  • Figure 8.7 Fecal Microbiota Therapies Developers: Distribution by Year of Establishment
  • Figure 8.8 Fecal Microbiota Therapies Developers: Distribution by Company Size
  • Figure 8.9 Fecal Microbiota Therapies Developers: Distribution by Location of Headquarters
  • Figure 9.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 9.2 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 9.3 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since Pre 2015
  • Figure 9.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since Pre 2015
  • Figure 9.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
  • Figure 9.6 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
  • Figure 9.7 Clinical Trial Analysis: Distribution by Study Design
  • Figure 9.8 Leading Industry Players: Distribution by Number of Registered Trials
  • Figure 9.9 Leading Non-industry Players: Distribution by Number of Registered Trials\
  • Figure 9.10 Clinical Trial Analysis: Analysis by Trial Location
  • Figure 9.11 Clinical Trial Analysis: Analysis by Trial Status and Geography
  • Figure 10.1 AC Matrix: Pictorial Representation
  • Figure 10.2 AC Matrix: Positioning of Different Indications
  • Figure 11.1 Benchmarking of Start-ups: Distribution by Portfolio Diversity
  • Figure 11.2 Benchmarking of Start-ups: Distribution by Phase of Development
  • Figure 11.3 Benchmarking of Start-ups: Distribution by Indication Diversity
  • Figure 11.4 Benchmarking of Start-ups: Distribution by Funding Amount
  • Figure 11.5 Benchmarking of Start-ups: Distribution by Partnership Activity
  • Figure 11.6 Start-up Health Indexing: Roots Analysis Perspective
  • Figure 11.7 Start-up Heal Indexing: Leading Companies
  • Figure 12.1 Diabetes: Diagnostic Limits for Plasma Glucose Levels
  • Figure 12.2 Non-Insulin Therapies for Diabetes
  • Figure 12.3 Weight Categories as per BMI Calculations
  • Figure 12.4 Causes of Obesity in Children
  • Figure 12.5 Obese Population: Distribution by Key Regions
  • Figure 13.1 Partnerships and Collaborations: Distribution of Cumulative Year-wise Trend, Since 2017
  • Figure 13.2 Partnerships and Collaborations: Distribution of Type of Partnership
  • Figure 13.3 Partnerships and Collaborations: Distribution of Year and Type of Partnership, Since 2017
  • Figure 13.4 Partnerships and Collaborations: Distribution of Type of Collaborator
  • Figure 13.5 Partnerships and Collaborations: Distribution of Target Indication
  • Figure 13.6 Partnerships and Collaborations: Distribution by Type of Partnership and Target Indication
  • Figure 13.7 Partnerships and Collaborations: Distribution of Therapeutic Area
  • Figure 13.8 Most Active Players: Distribution by Number of Partnerships
  • Figure 13.9 Partnerships and Collaborations: Distribution by Type of Agreement (Country wise)
  • Figure 13.10 Partnerships and Collaborations: Distribution by Type of Agreement (Region wise)
  • Figure 13.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 14.1 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested (USD Million), Since 2017
  • Figure 14.2 Funding and Investment Analysis: Distribution by Year of Establishment and Type of Funding, Since 2017
  • Figure 14.3 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, Since 2017
  • Figure 14.4 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested (USD Million), Since 2017
  • Figure 14.5 Funding and Investment Analysis: Distribution by Type of Funding
  • Figure 14.6 Funding and Investment Analysis: Distribution by Year and Type of Funding
  • Figure 14.7 Funding and Investment Analysis: Distribution by Type of Funding and Amount Invested (USD Million)
  • Figure 14.8 Funding and Investment Analysis: Distribution by Purpose of Funding
  • Figure 14.9 Funding and Investment Analysis: Distribution by Type of Product
  • Figure 14.10 Funding and Investment Analysis: Distribution by Target Indication
  • Figure 14.11 Funding and Investment Analysis: Distribution by Therapeutic Area
  • Figure 14.12 Funding and Investment Analysis: Distribution by Type of Product, Type of Funding and Amount Invested (USD Million)
  • Figure 14.13 Funding and Investment Analysis: Distribution by Region
  • Figure 14.14 Most Active Players: Distribution by Number of Instances
  • Figure 14.15 Most Active Players: Distribution by Amount Raised (USD Million)
  • Figure 14.16 Key Investors: Distribution by Number of Funding Instances
  • Figure 14.17 Funding and Investment Summary, Since 2017 (USD Million)
  • Figure 15.1 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Year of Establishment
  • Figure 15.2 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Company Size
  • Figure 15.3 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Headquarters
  • Figure 15.4 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation
  • Figure 15.5 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Product Manufactured
  • Figure 15.6 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation
  • Figure 15.7 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
  • Figure 16.1 Big Data: The Three V's
  • Figure 16.2 Internet of Things: Framework
  • Figure 16.3 Internet of Things: Applications in Healthcare
  • Figure 16.4 Big Data: Google Trends Analysis
  • Figure 16.5 Big Data and Microbiome: Google Trends
  • Figure 16.6 Big Data: Key Application Areas
  • Figure 16.7 Big Data: Opportunities in Healthcare
  • Figure 16.8 Big Data: Key Benefits for Pharmaceutical and Biotechnology Products
  • Figure 16.9 Challenges Associated with Microbiome-related Big Data Management
  • Figure 17.1 Global Human Microbiome Therapeutics Market, Till 2035 (USD Billion)
  • Figure 17.2 Human Microbiome Therapeutics Market: Distribution by Type of Product (USD Million)
  • Figure 17.3 Human Microbiome Therapeutics Market for Probiotic Drugs, Till 2035 (USD Million)
  • Figure 17.4 Human Microbiome Therapeutics Market for Other Drugs, Till 2035 (USD Million)
  • Figure 17.5 Human Microbiome Therapeutics Market: Distribution by Target Disease Indication
  • Figure 17.6 Human Microbiome Therapeutics Market for Recurrent C. difficile Infection, Till 2035 (USD Million)
  • Figure 17.7 Human Microbiome Therapeutics Market for Necrotizing Enterocolitis, Till 2035 (USD Million)
  • Figure 17.8 Human Microbiome Therapeutics Market for Primary Hyperoxaluria, Till 2035 (USD Million)
  • Figure 17.9 Human Microbiome Therapeutics Market for Graft versus Host Disease, Till 2035 (USD Million)
  • Figure 17.10 Human Microbiome Therapeutics Market: Distribution by Therapeutic Area (USD Million)
  • Figure 17.11 Human Microbiome Therapeutics Market for Infectious Diseases, Till 2035 (USD Million)
  • Figure 17.12 Human Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, Till 2035 (USD Million)
  • Figure 17.13 Human Microbiome Therapeutics Market for Rare Disorders, Till 2035 (USD Million)
  • Figure 17.14 Human Microbiome Therapeutics Market: Distribution by Route of Administration (USD Million)
  • Figure 17.15 Human Microbiome Therapeutics Market for Oral Therapeutics, Till 2035 (USD Million)
  • Figure 17.16 Human Microbiome Therapeutics Market for Rectal Therapeutics, Till 2035 (USD Million)
  • Figure 17.17 Human Microbiome Therapeutics Market: Distribution by Type of Formulation (USD Million)
  • Figure 17.18 Human Microbiome Therapeutics Market for Capsules, Till 2035 (USD Million)
  • Figure 17.19 Human Microbiome Therapeutics Market for Suspensions, Till 2035 (USD Million)
  • Figure 17.20 Human Microbiome Therapeutics Market for Enemas, Till 2035 (USD Million)
  • Figure 17.21 Human Microbiome Therapeutics Market: Distribution by Key Geographical Regions, Till 2035 (USD Million)
  • Figure 17.22 Human Microbiome Therapeutics Market in North America, Till 2035 (USD Million)
  • Figure 17.23 Human Microbiome Therapeutics Market in Europe, Till 2035 (USD Million)
  • Figure 17.24 Human Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, Till 2035 (USD Million)
  • Figure 17.25 Human Microbiome Therapeutics Market: Distribution by Leading Drug Developers, Till 2035 (USD Million)
  • Figure 17.26 Sales Forecast: SER-109, Till 2035 (USD Million)
  • Figure 17.27 Sales Forecast: RBX2660, Till 2035 (USD Million)
  • Figure 17.28 Sales Forecast: CP101, Till 2035 (USD Million)
  • Figure 17.29 Sales Forecast: IBP-9414, Till 2035 (USD Million)
  • Figure 17.30 Sales Forecast: Oxabact, Till 2035 (USD Million)
  • Figure 17.31 Sales Forecast: MaaT013, Till 2035 (USD Million)
  • Figure 18.1 Overall Microbiome Diagnostics Market, Till 2035 (USD Million)
  • Figure 18.2 Microbiome Diagnostics Market: Distribution by Target Indications, Till 2035 (USD Million)
  • Figure 18.3 Microbiome Diagnostics Market for Irritable Bowel Syndrome, Till 2035 (USD Million)
  • Figure 18.4 Microbiome Diagnostics Market for Inflammatory Bowel Disease, Till 2035 (USD Million)
  • Figure 18.5 Microbiome Diagnostics Market for Colorectal Cancer, Till 2035 (USD Million)
  • Figure 18.6 Microbiome Diagnostics Market for Diabetes Mellitus, Till 2035 (USD Million)
  • Figure 18.7 Microbiome Diagnostics Market: Distribution by Therapeutic Areas, Till 2035 (USD Million)
  • Figure 18.8 Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, Till 2035 (USD Million)
  • Figure 18.9 Microbiome Diagnostics Market for Oncological Disorders, Till 2035 (USD Million)
  • Figure 18.10 Microbiome Diagnostics Market for Metabolic Disorders, Till 2035 (USD Million)
  • Figure 18.11 Microbiome Diagnostics Market: Distribution by Key Geographical Regions, Till 2035 (USD Million)
  • Figure 18.12 Microbiome Diagnostics Market in North America, Till 2035 (USD Million)
  • Figure 18.13 Microbiome Diagnostics Market in Europe, Till 2035 (USD Million)
  • Figure 18.14 Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, Till 2035 (USD Million)
  • Figure 19.1 Global Fecal Microbiota Therapies Market, Till 2035 (USD Million)
  • Figure 19.2 Global Microbiota Therapies Market, Till 2035 (Million Procedures)
  • Figure 19.3 Fecal Microbiota Therapies Market in North America, Till 2035 (USD Million)
  • Figure 19.4 Fecal Microbiota Therapies Market in Europe, Till 2035 (USD Million)
  • Figure 19.5 Fecal Microbiota Therapies Market in Asia Pacific, Till 2035 (USD Million)
  • Figure 19.6 Fecal Microbiota Therapies Market in North America, Till 2035 (Million Procedures)
  • Figure 19.7 Fecal Microbiota Therapies in Europe, Till 2035 (Million Procedures)
  • Figure 19.8 Fecal Microbiota Therapies Market in Asia Pacific, Till 2035 (Million Procedures)
  • Figure 19.9 Overall Human Microbiome Market: Distribution by Product Offerings (USD Million)
  • Figure 21.1 Concluding Remarks: Human Microbiome Therapeutics Landscape
  • Figure 21.2 Concluding Remarks: Human Microbiome Therapeutics Landscape
  • Figure 21.3 Concluding Remarks: Human Microbiome Diagnostics Landscape
  • Figure 21.4 Concluding Remarks: Fecal Microbiota Therapies Landscape
  • Figure 21.5 Concluding Remarks: Funding and Investment Analysis
  • Figure 21.6 Concluding Remarks: Partnerships and Collaborations
  • Figure 21.7 Concluding Remarks: Start-up Health Indexing
  • Figure 21.8 Concluding Remarks: Human Microbiome Market Sizing and Opportunity Analysis
  • Figure 21.9 Concluding Remarks: Microbiome Therapeutics Market Sizing and Opportunity Analysis
  • Figure 21.10 Concluding Remarks: Microbiome Diagnostic Tests Market Sizing and Opportunity Analysis
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!